In a retrospective case series including 27 patients with MS, concurrent use of disease‐modifying therapy and anti‐CGRP mAbs was not associated with the worsening of MS symptoms, and only mild AEs occurred in 11% of patients (i.e., muscle spasms and constipation) [8]. This evidence concerns the gene CALCA and myeloid sarcoma.